ARTICLE | Clinical News
Sanctura: Phase III data
August 30, 2004 7:00 AM UTC
In a double-blind U.S. Phase III trial in 658 patients, Sanctura reduced OAB symptoms but did not significantly alter daytime sleepiness scores compared to placebo. FDA approved Sanctura to treat OAB ...